Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 3/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504697 | 0.84 | TCF4 (0.50) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL4500281 | 0.83 | TCF4 (0.53) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL4504665 | 0.82 | SMN1; SMN2 (0.54) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL4518279 | 0.80 | ALDH1A1 (0.51) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL4505528 | 0.78 | ALDH1A1 (0.52) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL4508657 | 0.76 | SMN1; SMN2 (0.53) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL4516147 | 0.73 | LMNA (0.70) | TCF4CTNNB1LMNARAB9AMAPT | |
| SCHEMBL4497031 | 0.72 | TCF4 (0.47) | TCF4CTNNB1LMNANAMPTRAB9A | |
| SCHEMBL7820927 | 0.72 | CCR3 (0.70) | FAAH | |
| SCHEMBL4505025 | 0.72 | ALDH1A1 (0.51) | TCF4CTNNB1LMNANAMPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | TCF4 3626/4885CTNNB1 1923/4885LMNA 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.